AIVI1.533%
as of Jul 17
GSK
DefensiveGSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer.
Close · 3M
-9.85%
Held by 2 AI ETFs
PQNT0.550%
as of Jul 21
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals6
Win rate0% (0/6)
Avg buy return-3.43%
AIVI · Weight decrease · 5d
GSK currently trades at $52.77, sitting at 86% of its 52-week high of $61.18, following a strong 1-year return of +38.2% but a slight dip of -4.9% over the past 90 days. AIVI, managed by WisdomTree, employs an AI overlay to select developed-international value stocks within its portfolio. The AI's model likely flagged GSK as its valuation changed, with the stock's significant appreciation over the last year potentially diminishing its attractiveness as a value play relative to other opportunities in the fund's international developed-market pool. Consequently, the fund executed a consecutive weight decrease from 1.5741% on July 10th to 1.5300% on July 15th, reflecting the AI's periodic rebalancing adjustments to align with its core value-factor methodology. This gradual reduction indicates the AI's system is systematically realigning its allocation away from a stock that has moved higher towards its valuation limits.
weight 1.602% → 1.530% (-0.072 pp)·stock down 3.0% in the 30 days before
Jul 15·entry $51.45·now $50.04
-2.74%
since Jul 15
AIVI · Weight decrease · 4d
WisdomTree's AIVI, which uses AI selection within a universe of approximately 100 international developed-market value stocks, appears to be strategically reducing its allocation to GSK. The consecutive weight decrease, moving from 1.5741% to 1.5320% over recent trading days, suggests the AI overlay is actively trimming its exposure. Considering GSK's strong performance, evidenced by a +33.6% 1-year return, the AI model may perceive the stock as less aligned with the fund's value-factor criteria at its current $51.45 price point. This nuanced adjustment, even with AIVI's periodic rebalance schedule, indicates the AI's continuous evaluation of holdings to maintain its international value mandate.
weight 1.602% → 1.532% (-0.070 pp)·stock down 3.0% in the 30 days before
Jul 14·entry $51.25·now $50.04
-2.36%
since Jul 14
AIVI · Weight decrease · 3d
GSK is trading at $51.25, approximately 84% of its 52-week high, following a 3.9% return in the last 30 days and a 31.6% gain over the past year. This upward price trajectory likely signals a shift in GSK's valuation profile according to AIVI's AI selection methodology, which focuses on developed-international value stocks. The fund's AI overlay has responded by initiating consecutive weight reductions, from 1.5983% on July 8th to 1.5667% on July 13th. This move suggests the AI's models determined GSK's current valuation no longer aligns as strongly with AIVI's value-factor criteria, prompting a rebalancing away from the stock at this higher price point.
weight 1.602% → 1.567% (-0.035 pp)·stock up 2.2% in the 30 days before
Jul 13·entry $52.29·now $50.04
-4.30%
since Jul 13
AIVI · Weight decrease · 2d
GSK, currently priced at $52.29 and trading at 85% of its 52-week high after a 1-year return of +36.2%, likely presented a reduced value proposition to AIVI's AI selection method. Despite a recent -8.0% 90-day return, the AI's periodic rebalancing, designed for an international developed-market value-factor pool, seems to have weighed GSK's longer-term appreciation more heavily. The consecutive weight decrease detected between 2026-07-08 (1.5983%) and 2026-07-10 (1.5741%) indicates the AI's overlay shifted capital away from GSK, preferring other holdings within its ~100-stock portfolio as stronger value candidates. This adjustment specifically reflects the AI's current assessment of GSK's attractiveness against its value criteria, distinguishing AIVI's unique approach in an underserved market corner.
weight 1.602% → 1.574% (-0.028 pp)·stock up 3.0% in the 30 days before
Jul 10·entry $52.78·now $50.04
-5.19%
since Jul 10
AIVI · Weight decrease · 4d
GSK is currently priced at $50.67, placing it at 83% of its 52-week high of $61.18, following a 90-day return of -13.9% contrasted with a 1-year return of +23.0%. This price action, showing a significant annual climb followed by a recent pullback, likely shaped the perspective of AIVI's AI selection algorithm, which focuses on international developed-market value stocks. As the WisdomTree-managed AI periodically rebalances its portfolio from its value-factor pool, GSK's consecutive weight decrease from 1.5576% on June 15 to 1.5159% on June 18 suggests the algorithm found its valuation less attractive relative to other opportunities or that its value characteristics diminished within the model. The AI's decisions, rather than daily market fluctuations, drive these measured adjustments within the ETF.
weight 1.598% → 1.516% (-0.082 pp)·stock down 0.7% in the 30 days before
Jun 18·entry $50.67·now $50.04
-1.24%
since Jun 18
AIVI · Weight decrease · 3d
GSK is currently priced at $52.15, representing 85% of its 52-week high of $61.18, reflecting a 30-day return of +3.2% and a one-year return of +26.7%, despite a 90-day decline of 11.6%. WisdomTree's AIVI, managed by an AI system selecting from a developed-international value-factor pool, targets approximately 100 international developed-market value stocks. The AI-driven rebalancing appears to have evaluated GSK's valuation within this specific framework, possibly considering its proximity to the 52-week high after a significant upward trajectory over the past year. Following a weight of 1.5931% on 2026-06-12, the fund's AI system consequently decreased GSK's allocation to 1.5576% by 2026-06-15, and further to 1.5458% on 2026-06-16, indicating a consecutive reduction as the stock's perceived value factor shifted within the AI's selection criteria. This move suggests the AI manager identified GSK as potentially less aligned with its value mandate at this elevated price point after its recent performance.
weight 1.598% → 1.546% (-0.052 pp)·stock up 5.1% in the 30 days before
Jun 16·entry $52.22·now $50.04
-4.17%
since Jun 16
AIVI · Weight decrease · 2d
AIVI exhibits a gentle, two-step reduction in GSK's weight, moving from 1.5975% to 1.5576% across recent rebalancing points, occurring as the stock trades at $52.23, 85% of its 52-week high. This gradual scaling back is consistent with an AI selection process within an international value framework, especially since the health care company has delivered a 29.1% return over the past year. The artificial intelligence, continuously assessing developed-international value stocks for this WisdomTree fund, likely perceives a diminished value proposition for GSK as its price ascended, prompting the subtle decrease in allocation during AIVI’s periodic rebalances rather than daily adjustments. This vigilance ensures the fund maintains its specific focus on a comparatively underserved international value segment.
weight 1.598% → 1.558% (-0.040 pp)·stock up 2.5% in the 30 days before
Jun 15·entry $52.23·now $50.04
-4.19%
since Jun 15
AIVI · Accumulation · 5d
GSK trades at $53.04, placing it at 87% of its 52-week high of $61.18, following a +2.8% 30-day return and a -7.3% 90-day return, though its one-year return is +27.3%. This specific setup likely prompted WisdomTree's AIVI, an AI-managed international value ETF, to engage in gradual accumulation. The AI's selection process, operating within its developed-international value-factor pool, likely identified the recent 90-day decline as an entry point, despite the current position near the 52-week high. The observed incremental increases in GSK's weight from 1.4968% to 1.5931% over ten days align with AIVI's periodic rebalancing as the AI model confirmed the stock met its value criteria. The fund's AI appears to assess that GSK, a UK-based healthcare company, maintains its value appeal within the international value segment, even as it recovers.
weight 1.497% → 1.593% (+0.096 pp)·stock up 4.0% in the 30 days before
Jun 12·entry $53.04·now $50.04Fresh
-5.66%
since Jun 12
AIVI · Accumulation · 5d
GSK's 1-year return of 28.8% demonstrates significant growth, yet its 90-day return of -0.9% suggests a recent period of consolidation, a characteristic aligning with WisdomTree's AIVI international value selection. The AI selection process within this developed-international value-factor ETF likely identified GSK at its current price of $52.86, which is 86% of its 52-week high, as offering a value opportunity following its quarterly underperformance. This led to a gradual accumulation in early June 2026, with AIVI's weight in GSK increasing from 1.5114% to 1.5975%, indicating the AI's rebalancing algorithm viewed the stock as meeting its criteria at those specific price levels after its recent stagnation.
weight 1.511% → 1.597% (+0.086 pp)·stock up 3.9% in the 30 days before
Jun 11·entry $52.86·now $50.04Fresh
-5.33%
since Jun 11
AIVI · Weight increase · 3d
weight 1.497% → 1.597% (+0.100 pp)·stock up 2.0% in the 30 days before
Jun 5·entry $51.52·now $50.04Fresh
-2.87%
since Jun 5
AIVI · Weight increase · 2d
weight 1.497% → 1.565% (+0.069 pp)·stock up 1.8% in the 30 days before
Jun 4·entry $51.27·now $50.04Fresh
-2.40%
since Jun 4
AIVI · Weight decrease · 5d
GSK is currently trading at $49.00, approximately 80% of its 52-week high of $61.18, following a 12.7% decline over the past 30 days, despite a 27.6% gain over the last year. WisdomTree’s AIVI, which employs AI selection within a developed-international value-factor pool, appears to be actively managing its exposure to the Health Care company. The fund's AI overlay likely reassessed GSK's standing within its value framework, prompting a series of weight reductions from 1.6948% on May 15 to 1.4968% on June 2. This sustained decrease in allocation suggests the AI algorithm is responding to the stock's recent price underperformance, aligning the portfolio's international value focus with the AI's current assessment of GSK's risk-adjusted prospects. The periodic rebalancing of AIVI thus reflects a timely adjustment to GSK's evolving price and perceived value characteristics.
weight 1.732% → 1.497% (-0.235 pp)·stock down 5.1% in the 30 days before
Jun 2·entry $49.00·now $50.04
+2.12%
since Jun 2
AIVI · Weight decrease · 4d
GSK's 30-day return of -14.0% leading into June, bringing its price to $49.31, prompted a significant re-evaluation by the AI managing AIVI, which targets developed-international value stocks. The AI-driven selection for this WisdomTree ETF initiated consecutive weight reductions on GSK from May 13th to 15th, followed by a more substantial adjustment on June 1st, decreasing its allocation from 1.7050% to 1.5114%. Despite GSK's 1-year return of +29.9%, the recent price decline likely triggered AIVI's algorithm to reassess the company's value characteristics, signaling a deterioration in its value-factor ranking within the portfolio rather than identifying a deeper value opportunity. This behavior demonstrates how AIVI, which holds roughly 100 international developed-market value stocks, dynamically adjusts its portfolio through periodic rebalances in response to evolving financial metrics and market conditions specific to each holding like GSK.
weight 1.732% → 1.511% (-0.221 pp)·stock down 5.7% in the 30 days before
Jun 1·entry $49.31·now $50.04
+1.48%
since Jun 1
AIVI · Weight decrease · 3d
GSK, currently priced at $50.54, is positioned at 83% of its 52-week high of $61.18, following a 34.3% return over the past year. This sustained price appreciation indicates that the AI managing AIVI, which focuses on international value stocks, may have re-evaluated GSK's relative attractiveness within its developed-international value-factor pool. The consecutive weight decreases from 1.7186% on May 13 to 1.6948% on May 15 demonstrate the AI's systematic de-emphasis of GSK, even as the stock experienced a -13.4% return over the prior 30 days. This pattern suggests the AI recalibrated GSK’s portfolio share, likely finding its valuation less compelling for its value mandate despite recent price movements.
weight 1.732% → 1.695% (-0.037 pp)·stock down 13.1% in the 30 days before
May 15·entry $49.67·now $50.04
+0.74%
since May 15
AIVI · Weight decrease · 2d
The AI ETF likely implemented this consecutive weight decrease in GSK because its algorithm detected weakening quantitative signals, such as deteriorating fundamentals or negative technical momentum. This indicates the AI is actively de-risking or reallocating capital based on its predictive models' assessment of future performance or increased risk. For retail investors, observing an AI fund consistently reducing exposure to a stock like GSK should prompt their own independent due diligence on the company's recent developments and outlook, rather than blindly following the trend.
weight 1.732% → 1.702% (-0.030 pp)·stock down 11.8% in the 30 days before
May 14·entry $50.96·now $50.04
-1.81%
since May 14
AIVI · Weight decrease · 5d
The AI ETF likely implemented this consecutive weight decrease for GSK due to identified negative momentum or deteriorating fundamental signals, prompting a systematic reduction in exposure. This indicates the algorithm perceives ongoing headwinds for the company, reallocating capital to potentially stronger performers or reducing overall portfolio risk. For a retail investor, this pattern serves as a warning sign, suggesting further independent research into GSK's recent performance and relevant news is prudent before investing.
weight 1.778% → 1.694% (-0.085 pp)·stock down 14.4% in the 30 days before
May 11·entry $49.81·now $50.04
+0.46%
since May 11
AIVI · Weight decrease · 4d
The AI ETF's consecutive weight decrease in GSK likely stems from its models detecting persistent negative signals, such as deteriorating fundamentals, adverse clinical trial outcomes, or increased competitive pressure within the healthcare sector, leading to a systematic de-risking. For retail investors, this pattern signals a critical need to perform immediate, thorough due diligence on GSK's recent news and financial reports, prompting a re-evaluation of their investment thesis given the AI's perceived increase in risk or diminished growth prospects.
weight 1.778% → 1.698% (-0.080 pp)·stock down 13.6% in the 30 days before
May 8·entry $50.41·now $50.04
-0.73%
since May 8
-0.91%
since May 7
-0.97%
since May 6
-3.04%
since May 1
-4.34%
since Apr 30
PQNT · Weight increase · 2d
GSK trades at $51.76, holding 85% of its 52-week high, having delivered a +35.5% return over the past year despite a 90-day slide of -6.4% and a recent 30-day uptick of +1.0%. This newer Pictet-managed ETF, PQNT, incorporates AI signals alongside factor exposures like momentum and sentiment across its international developed-market universe. Given GSK's position—a significant annual gain with a recent short-term negative drift beginning to reverse—the AI system likely identified a specific inflection point or strengthening factor signals for the stock. This probable detection of renewed positive momentum or improving sentiment for GSK within the Health Care sector would drive PQNT's periodic rebalancing mechanism, leading to the consecutive weight increases to 0.55% and 0.56% seen on July 17th and 18th.
weight 0.500% → 0.560% (+0.060 pp)·stock down 0.9% in the 30 days before
Jul 18·entry $50.04·now $50.04Fresh
0.00%
since Jul 18
PQNT · Weight decrease · 3d
The AI ETF's consecutive weight decrease in GSK suggests its algorithms identified a deteriorating outlook for the company, possibly due to accumulating negative fundamental signals such as increased litigation risk, disappointing drug pipeline updates, or a general weakening in its competitive position within the pharmaceutical sector. This consistent reduction indicates the AI's model continuously registered unfavorable data points, prompting a sustained de-risking in its exposure to GSK. Retail investors should view such consistent AI de-risking as a potential warning sign, prompting independent research into GSK's latest news, financial reports, and sector developments. It signals that underlying factors might be negatively impacting the stock's future prospects, warranting a critical review of one's own investment thesis for GSK.
weight 0.470% → 0.440% (-0.030 pp)·stock down 13.6% in the 30 days before
May 10·entry $49.81·now $50.04
+0.46%
since May 10
PQNT · Weight decrease · 2d
The AI likely reduced GSK's weight consecutively after detecting deteriorating financial indicators, increased competitive risk, or a negative shift in its sector outlook, signaling a decrease in its attractiveness. Retail investors should view this as a clear signal to conduct their own thorough research into GSK's recent performance and news, rather than blindly following the AI's actions, to validate any underlying issues.
weight 0.470% → 0.450% (-0.020 pp)·stock down 13.6% in the 30 days before
May 8·entry $50.41·now $50.04
-0.73%
since May 8
-4.34%
since Apr 30
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.